Skip to content

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

PyloPlus Urea Breath Test System Pediatric Safety and Efficacy Study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05276557
Enrollment
40
Registered
2022-03-11
Start date
2022-11-17
Completion date
2023-06-30
Last updated
2023-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori, Safety, Efficacy

Brief summary

This is a multi-center, non-randomized, open label study. Subjects will be enrolled on a walk-in basis. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. All children will be exposed to non-radioactive 13C-Urea with citric acid, and shall submit a stool sample. Centers will house a PyloPlus UBT Analyzer to document results. PyloPlus Analyzer results shall remain blinded to the investigator and treating physician. No patient management decisions should be made based on the investigational PyloPlus® UBT System. Treating physician will prescribe a H. Pylori Stool Antigen Test to Stool test at either LabCorp or Quest Diagnostic, for the patient, which will be used for diagnostic purposes by the ordering physician. Total duration of study is anticipated to be approximately 6 months.

Interventions

COMBINATION_PRODUCTPyloPlus Urea Breath Test System

System containing a kit containing 13C urea and breath collection bags, and an analyzer to test breath samples pre and post 13C ingestion.

DIAGNOSTIC_TESTStool Antigen Test

An antigen test performed via a laboratory to test patients' stool for H. pylori

Sponsors

ARJ Medical, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
3 Years to 17 Years
Healthy volunteers
Yes

Inclusion criteria

* Male or female age 3-17 at the time of visit * Subject/Legal guardian (and subject when relevant) is willing to sing the Informed Consent/Assent Form * Naive to H. pylori treatment in the past 4 weeks

Exclusion criteria

* Pregnant and/or lactating women * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient of the quality of data * Participation in other interventional trials * Allergy to test substrates * Antibiotics taken within 4 weeks of the testing * Study subjects shall not consume the following items at least 1 hour prior to the PPUBT test: Mouthwash, Chewing Gum, Carbonated Beverages, Cigarette Smoke, Acetone (to simulate the effect of ketone production that may result from some diets), Alcohol, Food * Children 12 years and older - to be excluded after a written notification from the sponsor is received at the site that the limit of (approx.) 1/3 of the sample size was achieved for this group

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with recorded adverse events24 hoursNumber of participants with recorded adverse events after performing urea breath test

Secondary

MeasureTime frameDescription
Percentage of Agreement7 daysPercentage of agreement between stool test reference standard and continuous urea breath test in assessing presence or absence of Helicobacter pylori infection

Countries

United States

Contacts

Primary ContactClinical Trial Manager
info@gulfcoastscientific.com877-855-4100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026